TY - JOUR
T1 - Head-to-Head Comparison of Aptamer- and Antibody-Based Proteomic Platforms in Human Cerebrospinal Fluid Samples from a Real-World Memory Clinic Cohort
AU - Puerta, Raquel
AU - Cano, Amanda
AU - García-González, Pablo
AU - García-Gutiérrez, Fernando
AU - Capdevila, Maria
AU - de Rojas, Itziar
AU - Olivé, Clàudia
AU - Blázquez-Folch, Josep
AU - Sotolongo-Grau, Oscar
AU - Miguel, Andrea
AU - Montrreal, Laura
AU - Martino-Adami, Pamela
AU - Khan, Asif
AU - Orellana, Adelina
AU - Sung, Yun Ju
AU - Frikke-Schmidt, Ruth
AU - Marchant, Natalie
AU - Lambert, Jean Charles
AU - Rosende-Roca, Maitée
AU - Alegret, Montserrat
AU - Fernández, Maria Victoria
AU - Marquié, Marta
AU - Valero, Sergi
AU - tárraga, Lluís
AU - Cruchaga, Carlos
AU - Ramírez, Alfredo
AU - Boada, Mercè
AU - Smets, Bart
AU - Cabrera-Socorro, Alfredo
AU - Ruiz, Agustín
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - High-throughput proteomic platforms are crucial to identify novel Alzheimer’s disease (AD) biomarkers and pathways. In this study, we evaluated the reproducibility and reliability of aptamer-based (SomaScan® 7k) and antibody-based (Olink® Explore 3k) proteomic platforms in cerebrospinal fluid (CSF) samples from the Ace Alzheimer Center Barcelona real-world cohort. Intra- and inter-platform reproducibility were evaluated through correlations between two independent SomaScan® assays analyzing the same samples, and between SomaScan® and Olink® results. Association analyses were performed between proteomic measures, CSF biological traits, sample demographics, and AD endophenotypes. Our 12-category metric of reproducibility combining correlation analyses identified 2428 highly reproducible SomaScan CSF measures, with over 600 proteins well reproduced on another proteomic platform. The association analyses among AD clinical phenotypes revealed that the significant associations mainly involved reproducible proteins. The validation of reproducibility in these novel proteomics platforms, measured using this scarce biomaterial, is essential for accurate analysis and proper interpretation of innovative results. This classification metric could enhance confidence in multiplexed proteomic platforms and improve the design of future panels.
AB - High-throughput proteomic platforms are crucial to identify novel Alzheimer’s disease (AD) biomarkers and pathways. In this study, we evaluated the reproducibility and reliability of aptamer-based (SomaScan® 7k) and antibody-based (Olink® Explore 3k) proteomic platforms in cerebrospinal fluid (CSF) samples from the Ace Alzheimer Center Barcelona real-world cohort. Intra- and inter-platform reproducibility were evaluated through correlations between two independent SomaScan® assays analyzing the same samples, and between SomaScan® and Olink® results. Association analyses were performed between proteomic measures, CSF biological traits, sample demographics, and AD endophenotypes. Our 12-category metric of reproducibility combining correlation analyses identified 2428 highly reproducible SomaScan CSF measures, with over 600 proteins well reproduced on another proteomic platform. The association analyses among AD clinical phenotypes revealed that the significant associations mainly involved reproducible proteins. The validation of reproducibility in these novel proteomics platforms, measured using this scarce biomaterial, is essential for accurate analysis and proper interpretation of innovative results. This classification metric could enhance confidence in multiplexed proteomic platforms and improve the design of future panels.
KW - Alzheimer’s disease
KW - Olink
KW - SomaScan
KW - biomarkers
KW - cerebrospinal fluid
KW - mild cognitive impairment
KW - proteomics
UR - https://www.scopus.com/pages/publications/85214508578
U2 - 10.3390/ijms26010286
DO - 10.3390/ijms26010286
M3 - Article
C2 - 39796148
SN - 1661-6596
VL - 26
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 1
M1 - 286
ER -